PDF icon Download PDF
Semin Liver Dis 2014; 34(04): 427-434
DOI: 10.1055/s-0034-1394141
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence

Li-Chun Lu
1   Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan
2   Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
,
Ann-Lii Cheng
1   Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan
2   Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
3   Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
,
Ronnie T. P. Poon
4   Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
› Author Affiliations
Further Information

Publication History

Publication Date:
04 November 2014 (online)

   Permissions and Reprints
Preview

Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. Early-stage HCC can be curatively treated, but the recurrence rate remains high. To date, adjuvant treatments have not proven effective in preventing HCC recurrence after curative treatment. Although early studies explored the potential of vitamin K2, retinoid, chemotherapy, and recently, sorafenib, none of the studies reported successful outcomes. Several new lines of evidence have emerged to support the use of novel antiviral agents for preventing the recurrence of virus-related HCC after curative treatment. In this review, the authors provide a thorough overview of the various adjuvant treatments that have been attempted or are being considered for trial.

Keywords

hepatocellular carcinoma - prevention - recurrence - hepatitis B virus - hepatitis C virus - antiviral